Sept 30 (Reuters) - Kezar Life Sciences (KZR.O), opens new tab said on Monday it has paused a trial of its experimental drug for lupus to review safety data after four patients died in the mid ...

Now, the company has hit the brakes on its phase 2b study of the drug in lupus nephritis following four patient fatalities. An independent data monitoring committee (IDMC) recommended suspending ...

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN). Gazyva is an engineered humanized monoclonal antibody ...

Systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD, a group of intestinal disorders that cause inflammation of the digestive tract) share a common set of microbiome features that ...

Sept 24 (Reuters) - Biogen (BIIB.O), opens new tab and Belgian partner UCB (UCB.BR), opens new tab said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in ...